GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3

GeoVax Labs, Inc.

Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).
Cash $1.3M at March 31, 2026, down from $3.1M at Dec 31, 2025.
Phase 3 immunobridging study for GEO-MVA (mpox/smallpox) planned under EMA-aligned expedited pathway; enrollment ~500.
Completed cGMP manufacturing and fill/finish; CRO selected for trial initiation.
Exclusive license from Emory for Gedeptin in combination with immune checkpoint inhibitors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GeoVax Labs, Inc. reported the quarter ended March 31, 2026 results: net income $5.3 million.

Period: the quarter ended March 31, 2026
Net income: $5.3 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026, was $5.3 million

View on SEC.gov

4 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-017070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.